This collaboration provides validation for Perspective's PSV359 program from a top-tier pharma partner without dilutive financing. Monitor for initial safety/efficacy data from the combination cohorts as the next catalyst.
Price Chart
Executive Summary
Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors. Merck is providing pembrolizumab at no cost for the ongoing Phase 1/2a study, which has completed enrollment in the first three monotherapy dose cohorts. This is a non-financial, early-stage collaboration that provides drug supply and validation from a major pharma partner but involves no upfront payment or milestone commitment from Merck.
Key Facts
- Perspective Therapeutics entered a clinical collaboration and supply agreement with Merck (NYSE: MRK).
- Merck will supply Keytruda (pembrolizumab) at no cost for the combination study.
- The combination will be evaluated in an ongoing Phase 1/2a study of [212Pb]PSV359 in FAP-α positive non-small cell lung cancer and colorectal cancer.
- The study has completed enrollment in the first three monotherapy dose cohorts.
- Perspective is sponsoring the study.
Financial Impact
No financial terms disclosed; Merck is providing pembrolizumab at no cost. No upfront payment, milestone, or royalty commitments were announced.
Risk Factors
- Early-stage clinical risk — the combination has not yet generated human data.
- No financial commitment from Merck beyond drug supply; Merck can walk away at any time.
- The study is still in dose-finding; combination data may be years away.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-389785 |
| Document: catx-ex99_1.htm | 0001193125-26-389785 |
| Document: 0001193125-26-389785-index-headers.html | 0001193125-26-389785 |
| Document: 0001193125-26-389785-index.html | 0001193125-26-389785 |
| Document: 0001193125-26-389785.txt | 0001193125-26-389785 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers